Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems

Objective: Glucose-dependent insulinotropic polypeptide (GIP) is one of the two major incretin factors that regulate metabolic homeostasis. Genetic ablation of its receptor (GIPR) in mice confers protection against diet-induced obesity (DIO), while GIPR neutralizing antibodies produce additive weigh...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Bin Yang, Vasily M. Gelfanov, Kimberley El, Alex Chen, Rebecca Rohlfs, Barent DuBois, Ann Maria Kruse Hansen, Diego Perez-Tilve, Patrick J. Knerr, David D'Alessio, Jonathan E. Campbell, Jonathan D. Douros, Brian Finan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2022-12-01
coleção:	Molecular Metabolism
Assuntos:	Peptide antagonist GIP/GIPR GLP-1/GLP-1R Obesity Diabetes
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2212877822002071
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!